8-K: Celcuity Inc. Secures $201.25 Million Through Convertible Senior Notes Offering

Celcuity Inc. has successfully completed a public offering of $201.25 million aggregate principal amount of 2.750% Convertible Senior Notes due 2031, including the full exercise of the underwriters' over-allotment option.

Summary

• Celcuity Inc. issued and sold $175,000,000 aggregate principal amount of 2.750% Convertible Senior Notes due 2031.
• The underwriters exercised their option to purchase an additional $26,250,000 aggregate principal amount of Notes, bringing the total issued to $201,250,000.
• The offering was completed on August 1, 2025.
• The Notes are general, unsecured, senior obligations of the Company.
• Interest on the Notes accrues at a rate of 2.750% per year, payable semiannually in arrears on February 1 and August 1, beginning on February 1, 2026.
• The Notes will mature on August 1, 2031, unless earlier converted, redeemed, or repurchased.
• Noteholders may convert their Notes at an initial conversion rate of 19.4932 shares of common stock per $1,000 principal amount, equivalent to an initial conversion price of approximately $51.30 per share.
• The conversion rate is subject to customary adjustments, including increases for certain Make-Whole Fundamental Changes.
• The Company may redeem the Notes, in whole or in part, on or after August 6, 2029, if the common stock's last reported sale price exceeds 130% of the conversion price for at least 20 trading days within a 30-day period, and on the trading day immediately before the redemption notice.
• Noteholders have the right to require the Company to repurchase their Notes upon a Fundamental Change at a cash repurchase price equal to the principal amount plus accrued and unpaid interest.
• The net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses, were approximately $194.5 million.
• The Company intends to use the net proceeds for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, clinical trial expenditures, commercial launch expenditures, and expansion of business development activities.

Sentiment

Score: 7

Explanation: The successful completion of a significant convertible debt offering, including the full exercise of the over-allotment option, is a positive indicator of market confidence and provides substantial capital for the company's strategic initiatives, particularly in R&D and clinical trials. While it introduces debt and potential future dilution, the immediate capital infusion for growth outweighs these factors in the short term.

Positives

• Successfully raised $201.25 million in capital, including the full exercise of the over-allotment option, indicating strong market demand for the offering.
• The capital infusion provides significant funding for working capital and strategic growth initiatives, such as research and development, clinical trials, and commercial launch expenditures.
• The convertible nature of the notes offers potential for equity conversion, aligning with long-term shareholder interests if the company's stock price appreciates.

Negatives

• The issuance of convertible senior notes increases the company's overall debt burden and leverage.
• There is a potential for future dilution of existing shareholders if the notes are converted into common stock, especially if the conversion rate increases due to make-whole provisions.
• The 2.750% annual interest payments represent a recurring financial obligation for the company.

Risks

• Default in payment of principal, redemption price, fundamental change repurchase price, or interest on any Note.
• Failure to deliver required notices under the Indenture within specified periods.
• Failure to convert a Note in accordance with the Indenture within a specified period.
• Default in obligations related to consolidation, merger, or asset transfer under Article 6 of the Supplemental Indenture.
• Default in other obligations or agreements under the Indenture or Notes not cured within 60 days after notice.
• Default by the Company or any significant subsidiaries on indebtedness for borrowed money of at least $15,000,000.
• Certain bankruptcy, insolvency, or reorganization events involving the Company or any of its significant subsidiaries.
• Final judgments of at least $15,000,000 being rendered against the Company or any of its significant subsidiaries that are not discharged or stayed within 60 days.
• Noteholders' conversion rights are limited by a beneficial ownership limitation, initially 4.99% (adjustable up to 19.99%), preventing conversion if it would result in ownership exceeding this threshold.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes, which may include capital expenditures, research and development expenditures, clinical trial expenditures, commercial launch expenditures, and expansion of business development activities. This indicates a focus on funding ongoing operations and future growth initiatives.

Industry Context

This filing details a standard debt offering for a publicly traded company, likely in the biotechnology or pharmaceutical sector given the stated use of proceeds for 'clinical trial expenditures' and 'research and development expenditures'. It represents a common strategy for companies to raise capital for growth and operational needs, balancing debt financing with potential equity upside through the convertible feature. The terms of the convertible notes (e.g., 2.750% interest, 2031 maturity) are typical for such instruments in the current market environment.

Stakeholder Impact

• Shareholders: Potential for future dilution if the notes are converted into common stock, but the capital raise supports company growth, which could benefit shareholders long-term.
• Creditors (Noteholders): The notes are general, unsecured, senior obligations, providing a claim on company assets, and offer a fixed interest return.
• Employees: The capital infusion for R&D and clinical trials could support job stability and potential growth in these areas.

Next Steps

• The Company will use the net proceeds from the offering for working capital and general corporate purposes, including capital expenditures, research and development, clinical trial expenditures, commercial launch expenditures, and expansion of business development activities.
• The Company will make generally available an earnings statement covering at least twelve months beginning with the first fiscal quarter after the date of the Underwriting Agreement.
• The Company will reserve and keep available a number of shares of Common Stock equal to the Maximum Number of Underlying Securities for conversion.
• The Company will use commercially reasonable efforts to cause each Conversion Share, when delivered, to be admitted for listing on Nasdaq.

Key Dates

Recommendation

The successful capital raise provides Celcuity with significant funds for its operations and growth initiatives, which is a positive development. However, the issuance of convertible notes introduces potential future dilution for existing shareholders and adds to the company's debt burden. Given the nature of the notes (convertible, unsecured, senior), the immediate impact is likely neutral to slightly positive as it addresses funding needs without immediate equity dilution. A 'hold' recommendation reflects the balance between the positive capital infusion and the long-term considerations of debt and potential dilution, pending further operational updates and financial performance.

Keywords

Celcuity Inc., CELC, Convertible Senior Notes, Debt Offering, Capital Raise, Corporate Finance, SEC Filing, 8-K, Biotechnology, Pharmaceutical, Clinical Trials, Nasdaq, Jefferies, TD Securities, Leerink Partners